The 15th annual edition of BIO-Europe, the world’s largest stand-alone partnering event will gather leaders of the life science industry at the Wiener Messe on November 2–4, 2009 in Vienna, Austria to take dealmaking to a new level. Traditionally held in Germany, the shift of the BIO-Europe venue to Austria recognizes the emergence of the Read more »
Dr. Rainer Wessel
President and CEO, GANYMED
As some biotech industry leaders contemplate survival strategies for weathering the financial crisis, GANYMED Pharmaceuticals AG sprang the news at BIO-Europe of closing a EUR 65 million round of financing. The round was led by ATS Beteiligungsverwaltung GmbH, Munich, which was joined in the financing by Future Capital AG in Read more »
James Watson, the managing director and head of merchant banking for Burrill & Company, said he missed his wife’s birthday again this year to come to Mannheim to lead what has become a BIO-Europe tradition and one of the most popular features of the event’s conference program —A Day in the Life of Experienced Dealmakers.
Yet Read more »
Close to 10,000 meetings between life science executives were confirmed even before the doors opened for BIO-Europe 2008 in Mannheim-Heidelberg on November 17, an increase of 25% over last year’s event.
While participation increased 5% to a record 2,400 delegates attending the three-day event, it was the extraordinary growth in the number of meetings per delegate Read more »
Always provocative and never disappointing, the BIO-Europe opening plenary session has become a popular tradition of the conference program. This year’s session, led by Vaughn Kailian from MPM Capital, pondered the question: “Rethinking R&D: Can Big Pharma Address the Productivity Gap through Earlier Stage Collaborations?”
This productivity “gap” is a polite way of saying that Read more »
Working one-to-one, working in groups to close a deal. If it sounds like the world of business development, that’s because the 80 executives who completed an intensive Advanced Business Development Course in Heidelberg spent three days recreating problems and then solving them for successful outcomes.
Before reading more, stop and mark your calendar for Oct Read more »
Market signals are mixed but the take-home message from the Biotechnology Industry Organization (BIO) was clear: Alliances are now essential for capital formation among biotechnology companies with mergers and acquisitions increasingly more attractive.
“It is evident from the strong partnering activity at this event that there is an increased intention on the part of biotechnology and Read more »
Three big pharma companies, three renowned research institutions and 60 small and medium-sized biotech enterprises have joined together for focused research programs on advance diagnostics and stem cells.
The German federal government will invest EUR 40 million in research funding for the programs, having selected the Biotechnology Cluster Rhine-Neckar from among 38 competing proposals for a Read more »
Newsletter